首页> 外文期刊>The Journal of biological chemistry >Physiology of Consumption of Human Milk Oligosaccharides by Infant Gut-associated Bifidobacteria
【24h】

Physiology of Consumption of Human Milk Oligosaccharides by Infant Gut-associated Bifidobacteria

机译:婴幼儿肠道相关双歧杆菌消费人乳寡糖的生理学

获取原文
获取外文期刊封面目录资料

摘要

The bifidogenic effect of human milk oligosaccharides (HMOs) has long been known, yet the precise mechanism underlying it remains unresolved. Recent studies show that some species/subspecies of Bifidobacterium are equipped with genetic and enzymatic sets dedicated to the utilization of HMOs, and consequently they can grow on HMOs; however, the ability to metabolize HMOs has not been directly linked to the actual metabolic behavior of the bacteria. In this report, we clarify the fate of each HMO during cultivation of infant gut-associated bifidobacteria. Bifidobacterium bifidum JCM1254, Bifidobacterium longum subsp. infantis JCM1222, Bifidobacterium longum subsp. longum JCM1217, and Bifidobacterium breve JCM1192 were selected for this purpose and were grown on HMO media containing a main neutral oligosaccharide fraction. The mono- and oligosaccharides in the spent media were labeled with 2-anthranilic acid, and their concentrations were determined at various incubation times using normal phase high performance liquid chromatography. The results reflect the metabolic abilities of the respective bifidobacteria. B. bifidum used secretory glycosidases to degrade HMOs, whereas B. longum subsp. infantis assimilated all HMOs by incorporating them in their intact forms. B. longum subsp. longum and B. breve consumed lacto-N-tetraose only. Interestingly, B. bifidum left degraded HMO metabolites outside of the cell even when the cells initiate vegetative growth, which indicates that the different species/subspecies can share the produced sugars. The predominance of type 1 chains in HMOs and the preferential use of type 1 HMO by infant gut-associated bifidobacteria suggest the coevolution of the bacteria with humans.
机译:长期以来,人乳寡糖(HMOS)的双歧蛋白效果已知,但其仍未解决的精确机制仍未解决。最近的研究表明,双歧杆菌的一些物种/亚种性配备了遗传和酶组,致力于利用HMOS,因此它们可以在HMOS上生长;但是,代谢HMOS的能力尚未直接与细菌的实际代谢行为直接相关。在本报告中,我们在培养婴儿肠道相关双歧杆菌期间阐明了每个HMO的命运。双歧杆菌Bifidum JCM1254,双歧杆菌寿槽。 Infantis JCM1222,双歧杆菌亚级。为此目的选择Longum JCM1217和Bifidobacterium Brive JCM1192,并在含有主要中性低聚糖级分的HMO培养基上生长。用2-炭酸中的金属培养基中的单糖和寡糖标记,并使用正相高效液相色谱法在各种孵育时间测定它们的浓度。结果反映了相应双歧杆菌的代谢能力。 B. Bifidum使用的分泌糖苷酶降解HMOS,而B. Longum Subsp。 Infantis通过将它们纳入完整的形式来同化所有HMOS。 B. Longum Subsp。 Longum和B. Breve仅消耗了乳酸乳酸乳糖。有趣的是,B.甚至在细胞开始营养生长的情况下,Bifidum留下了细胞外的HMO代谢物,这表明不同的物种/亚种可以分享生产的糖。 HMO中1型链的优势和婴儿肠道相关双歧杆菌的1型HMO的优先使用表明细菌与人类的共同性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号